Breast Clinical Trials
Study Name: (CAPItello-292)
- Description: Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
- Study Number: D361DC00001
- FHH or Referral: Referral
- NCT#: NCT04862663
- Cancer Stage: IV
- Key Inclusion: HR+/HER2-